Methotrexate vs 5‐aminosalicylic acid (5‐ASA) (mesalazine): Failure to enter remission or possible remission at 16 weeks (Arora 1999)
It is very uncertain whether methotrexate changes failure to enter remission or possible remission at 30 weeks… compared with 5‐ASA (very low certainty).
What each review found
Include earlier review versions| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Methotrexate vs 5‐ASA Failure to enter remission or possible remission at 30 weeks (Maté‐Jiménez 2000) · Adult patients with refractory Crohn's disease It is very uncertain whether methotrexate changes failure to enter remission or possible remission at 30 weeks… compared with 5‐ASA (very low certainty). Methotrexate for induction of remission in refractory Crohn's disease (2014) · Cochrane Headline outcomes only | RR 0.23 [0.08, 0.67] | 1 study · 22 participants | Very low |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Methotrexate for induction of remission in refractory Crohn's disease 2014 · Cochrane Headline outcomes only | Not reported | list not extracted yet | Not assessed |
Studies behind the findings
None of these reviews ties its included studies to this outcome in the data here. Cochrane reviews and reviews with headline outcomes only do not list their studies yet.
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.